SNCA and Parkinson disease: Based on our unbiased discovery of SCD inhibitors in yeast and their protection against α-synuclein toxicity in neurons [5], we established a drug discovery program to identify novel potent, brain-penetrant SCD inhibitors for the treatment of Parkinson’s disease.